Star Therapeutics

Star team member Laura Guido, PharmD, MBA, BCPS visited Wisconsin this weekend for the Great Lakes Hemophilia Foundation conference. It was a meaningful opportunity to spend time with members of the bleeding disorders community and hear firsthand about the experiences that shape and inspire our work in VWD.

Today, we announced that we have entered into a definitive agreement for Incyte to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for up to $2.0 billion. The proposed acquisition would add VGA039, a novel monoclonal antibody in Phase 3 pivotal development for von Willebrand Disease (VWD), to Incyte’s hematology portfolio. More details here. https://lnkd.in/e-x6VQaT

If you or someone you know has been diagnosed with #vonWillebrandDisease, we want to connect with you. Our VIVID (VGA039 Investigation in von Willebrand Disease) Phase 3 clinical trial is now enrolling patients with any type of VWD aged 12-75. Learn more on our website. https://lnkd.in/exVVHJvP

Have you or your loved one been diagnosed with #vonWillebrandDisease? You may be eligible for the VIVID Phase 3 clinical trial. Learn more about our investigational medicine, VGA039, below and visit our website to connect with us for more. https://lnkd.in/e3JavCmd

"Are yours this heavy?" For many women & girls with VWD, extremely heavy, prolonged menstrual cycles are often dismissed as something they must “just deal with.” From a young age, avoiding social events & managing severe symptoms becomes the norm. Stephanie shares her story during #MenstrualHealth Awareness Month.

Clinical trials are not just about data, they're about people. Participation in research is often part of a larger journey shaped by personal advocacy and a desire to accelerate advances in care. Patients' voices are critical to this work. Thanks to all those contributing to advancements for the VWD community. #ClinicalTrialsDay

According to the American College of Obstetricians and Gynecologists (ACOG), heavy menstrual bleeding affects nearly all women with VWD. Cycles can often last for weeks at a time, require constant management & can lead to anemia. This #MenstrualHealth Awareness Month, stories like Jessica’s help bring visibility to journeys that too often go unheard.

We invite everyone impacted by #VWD to join us for the National Bleeding Disorders Foundation Wednesday Webinar series this week (May 6) to learn more about our novel, investigational therapy, VGA039. Our clinical development lead, Benjamin Kim, looks forward to sharing updates on the program. Register to join us here. https://lnkd.in/ejYGXBTQ

For those with VWD, the emotional toll of uncertainty, dismissal, and hopelessness can be just as burdensome as the physical symptoms. During #MentalHealthMonth, Matt shares the lifelong impact living with VWD has had on his mental health and navigating depression and anxiety.

Von Willebrand Disease often hides in plain sight - passed quietly through generations, undiagnosed and misuderstood. On World DNA Day, a reminder: genetics isn't abstract, its the key to finding patients who've been missed for decades. Earlier diagnosis, better outcomes. It starts with understanding the code. #WorldDNADay